97001 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Glucagons
Double-acylated GLP-1 compounds
#602Glucagon receptor agonists
#603Glucagon receptor agonists
#604PEPTIDE AGONISTS OF GLP-1 ACTIVITY
#605GLP-1/glucagon receptor co-agonists for medical use
#606ALBUMIN FUSION PROTEINS
#607Peptide pharmaceuticals for insulin resistance
#608Dipeptide Comprising a Non-Proteogenic Amino Acid
#609Stabilizied bioactive peptides and methods of identification, synthesis and use
#610Osmotic delivery device comprising an insulinotropic peptide and uses thereof
#611Stitched polypeptides
#612Double-acylated GLP-1 derivatives
#613Peptides hormone analogues derivable from preproglucagon
#614Novel Glucagon Analogues
#615Thioamide-modified peptides and uses thereof
#616Extended recombinant polypeptides and compositions comprising same
#617Methods of DNA constructs for high yield production of polypeptides
#618Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
#619EXENDIN-4 PEPTIDE ANALOGUES AS DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS
#620LONG ACTING PROTEINS AND PEPTIDES AND METHODS OF MAKING AND USING THE SAME
#621Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
#622Stable glucagon analogues and use for treatment of hypoglycaemia
#623Derivatives of GLP-1 like peptides, and uses thereof
#624MATING FACTOR ALPHA PRO-PEPTIDE VARIANTS
#625Anti-PCSK9-GLP-1 fusions and methods for use
#626Glucagon and GLP-1 co-agonist compounds
#627Antibody specifically binding to GLP-1 R and fusion protein thereof with GLP-1
#628Solid phase peptide synthesis via side chain attachment
#629Glucagon-like-peptide-2 (GLP-2) analogues
#630Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
#631GLUCAGON ANALOGUES
#632Novel Glucagon Analogues
#633Enterokinase cleavable polypeptides
#634PROTEASE RESISTANT PEPTIDES
#635Compound for treatment of severe hypoglycemia
#636Novel Compound for Treatment of Severe Hypoglycemia
#637Peptide compound for treatment of severe hypoglycemia
#638Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
#639GLUCAGON ANALOGUES
#640G-PROTEIN COUPLED RECEPTOR AGONISTS AND METHODS
#641Synthesis of cyclic imide containing peptide products
#642GLP-1 ANALOG FUSION PROTEIN AND PREPARATION METHOD AND USE THEREOF
#643GIP-GLP-1 dual agonist compounds and methods
#644Glucagon-GLP-1-GIP triple agonist compounds
#645Long-acting blood sugar decreasing fusion protein
#646Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders
#647Multivalent heteromultimer scaffold design and constructs
#648AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS
#649GLP-1 derivatives, and uses thereof
#650Composition for treating hyperlipidemia comprising oxyntomodulin derivative
#651GIP and GLP-1 co-agonist compounds
#652Fusion proteins comprising FGF-21 and GLP-1R agonist
#653Method of improving the pharmacokinetic profile of a therapeutic polypeptide and the use thereof
#654GIP AND GLP-1 RECEPTOR DUAL-AGONISTS FOR THE TREATMENT OF DIABETES
#655Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
#656OLIGOSACCHARIDE COMPOSITIONS, GLYCOPROTEINS AND METHODS TO PRODUCE THE SAME IN PROKARYOTES
#657EXENDIN-4 PEPTIDE ANALOGUES AS DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS
#658Coiled coil immunoglobulin fusion proteins and compositions thereof
#659Stabilized insulinotropic peptides and methods of use
#660Conjugate of biologically active polypeptide monomer and immunoglobulin Fc fragment with reduced receptor-mediated clearance, and the method for preparing the same
#661ALBUMIN FUSION PROTEINS
#662GLP-1 derivatives and uses thereof
#663Fusion Proteins With Dual Receptor Agonist Activities
#664GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAME
#665GENETICALLY-MODIFIED MICRO-ORGAN SECRETING A THERAPEUTIC PEPTIDE AND METHODS OF USE THEREOF
#666Acylated glucagon analogues
#667Glucagon analogs exhibiting GIP receptor activity
#668CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
#669Novel GLP-1 Derivatives
#670Stable GLP-1 based GLP-1/glucagon receptor co-agonists
#671Double-acylated GLP-1 derivatives
#672Coryneform bacterium and method for producing heterologous fusion proteins
#673GIP receptor-active glucagon compounds
#674Peptide compound
#675Therapeutic agents comprising a GLP-2 peptide and elastin-like peptides
#676LONG-LIVED POLYNUCLEOTIDE MOLECULES
#677INSULIN-INCRETIN CONJUGATES
#678Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
#679Glucagon analogues
#680Novel Glucagon Analogues
#681Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
#682Bovine fusion antibodies
#683GLUCAGON ANALOGUES
#684Glucagon/GLP-1 receptor co-agonists
#685Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
#686Method of treating stomach or bowel-related disorders by administering glucagon-like-peptide-2 (GLP-2) analogues
#687Novel Glucagon Analogues
#688Insulin secreting polypeptides
#689Exendin-4 derivatives as selective glucagon receptor agonists
#690Analogs of glucagon exhibiting GIP receptor activity
#691Polypeptide and imaging method
#692NOVEL GLP-1 RECEPTOR AGONISTS WITH CHOLESTEROL EFFLUX ACTIVITY
#693Albumin fusion proteins
#694Insulinotropic peptide derivative with modified N-terminal charge
#695GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY
#696Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
#697Dual GLP-1/glucagon receptor agonists derived from exendin-4
#698Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
#699Oxyntomodulin analogs
#700Glucagon/GLP-1 agonists for the treatment of obesity
#701GIP-GLP-1 dual agonist compounds and methods
#702Peptide analogues with branched amino acid probe(s)
#703Formulations comprising glucagon
#704Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
#705Bile acid oligomer conjugate for novel vesicular transport and use thereof
#706Peptide pharmaceuticals for insulin resistance
#707Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region
#708METHODS OF ENHANCING FUNCTIONING OF THE LARGE INTESTINE
#709ACYLATED GLUCAGON ANALOGUES
#710Glucose-regulating polypeptides and methods of making and using same
#711GLP-1 ANALOGUE, ITS PREPARATION METHODS AND USE THEREOF
#712Glucagon Analogs Exhibiting GIP Receptor Activity
#713Apolipoprotein AIV as an antidiabetic peptide
#714Peptide analogues of glucagon and GLP1
#715Generating targeted sequence diversity in fusion proteins
#716GLUCAGON-LIKE PEPTIDE-1 ANALOGUE MONOMER AND DIMER, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
#717Double-Acylated GLP-1 Derivatives with a Linker
#718Glucagon analogues
#719Albumin fusion proteins
#720Therapeutic Uses of Dogfish Glucagon and Analogues Thereof
#721Protein and protein conjugate for diabetes treatment, and applications thereof
#722Glucagon analogues
#723COMPOSITION FOR TREATING HYPERLIPIDEMIA COMPRISING OXYNTOMODULIN DERIVATIVE
#724Dual GLP-1/GIP receptor agonists
#725Dual GLP-1/glucagon receptor agonists
#726Non-acylated exendin-4 peptide analogues
#727Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
#728Compositions, methods and uses
#729METHODS TO RESTORE GLYCEMIC CONTROL
#730Double-acylated GLP-1 derivatives
#731Pegylated OXM variants
#732Long-acting polypeptides and methods of producing and administering same
#733C-terminal fragments of glucagon-like peptide-1 (GLP-1)
#734Double-acylated GLP-1 derivatives
#735Glucagon/GLP-1 receptor co-agonists
#736Glucagon-like-peptide-2 (GLP-2) analogues
#737Acylated glucagon analogues
#738Glucagon analogues
#739METHODS AND TREATMENT WITH GLP-1 RECEPTOR AGONISTS
#740SITE-SPECIFIC ENZYMATIC MODIFICATION OF EXENDINS AND ANALOGS THEREOF
#741Long-acting polypeptides and methods of producing and administering same
#742Formulations and Uses of Exendins and Exendin Agonist Analogs
#743EXENDINS AND EXENDIN AGONIST ANALOGS TO REGULATE GASTROINTESTINAL MOTILITY
#744Therapeutic agents comprising fusions of growth hormone and elastic peptides
#745GLUCAGON ANALOGUES
#746COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCERS
#747PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
#748Fusion proteins of superfolder green fluorescent protein and use thereof
#749METHOD FOR PURIFYING SOLID-PHASE SYNTHETIC CRUDE LIRAGLUTIDE
#750Compositions comprising glucagon analogs and methods of making and using the same
#751GLP-1 prodrugs
#752Carrier immunoglobulins
#753Carrier immunoglobulins
#754Orally administered plastid expressed cholera toxin B subunit-exendin 4 as treatment for type 2 diabetes
#755Glucagon-like peptide-1 derivatives and their pharmaceutical use
#756NOVEL COMPOUNDS AND THEIR EFFECTS ON FEEDING BEHAVIOUR
#757Efficient production of peptides
#758OXYNTOMODULIN ANALOGUES AND THEIR EFFECTS ON FEEDING BEHAVIOUR
#759Derivatives of GLP-1 like peptides, and uses thereof
#760TREATMENT OF HYPOGLYCEMIA
#761Alpha/beta-polypeptide analogs of glucagon-like peptide-1
#762Peptide compound
#763Method for solid phase synthesis of liraglutide
#764PEPTIDE AGONISTS OF GLP-1 ACTIVITY
#765POLYPEPTIDE FOR THE PROTECTION AGAINST HEART ISCHEMIA-REPERFUSION INJURY
#766MODIFIED PEPTIDES AND PROTEINS
#767GLP-1 derivatives
#768Propeptide-luciferase fusion proteins and methods of use thereof
#769Extended recombinant polypeptides and compositions comprising same
#770Truncated GLP-1 derivatives and their therapeutical use
#771Hybrid polypeptides with selectable properties
#772Engineered polypeptides having enhanced duration of action with reduced immunogenicity
#773Commensal bacteria as singal mediators within a mammalian host
#774Bovine fusion antibodies
#775DRUG FUSIONS AND CONJUGATES WITH EXTENDED HALF LIFE
#776GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS
#777Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists
#778Compounds and their effects on feeding behaviour
#779METHODS OF ENHANCING FUNCTIONING OF THE LARGE INTESTINE
#780Therapeutic agents comprising fusions of insulin and elastic peptides
#781Exendin-4 Derivatives as dual GLP1/GIP or trigonal GLP1/GIP/Glucagon Agonists
#782Methods of Treatment Using A Pentapeptide Derived From The C-Terminus Of Glucagon-Like Peptide 1 (GLP-1)
#783METHODS TO RESTORE GLYCEMIC CONTROL
#784Functionalized exendin-4 derivatives
#785Exendin-4 Derivatives
#786Glucagon/GLP-1 receptor co-agonists
#787AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
#788DRUG FUSIONS AND CONJUGATES
#789Val (8) GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome
#790Double-acylated GLP-1 derivatives
#791Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
#792N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS
#793Selective glucagon-like-peptide-2 (GLP-2) analogues
#794Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
#795GLUCAGON ANALOGUES
#796GLUCAGON ANALOGUES
#797Compositions Comprising Glucagon Analogs And Methods Of Making And Using The Same
#798Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
#799Engineered polypeptides having enhanced duration of action
#800Methods for production and purification of polypeptides
#801Stabilized bioactive peptides and methods of identification, synthesis, and use
#802Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders
#803Exendin-4 derivatives as dual GLP1/glucagon agonists
#804Double-acylated GLP-1 derivatives
#805Glucagon analogues
#806FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME
#807Polypeptide Conjugate
#808GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEA
#809Homodimeric Proteins
#810Modified exendins and exendin agonists
#811Novel Glucagon Analogues
#812Composition for the therapy of diabetes mellitus and adiposity
#813Stitched polypeptides
#814Glucagon analogs exhibiting GIP receptor activity
#815COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES
#816Peptides derivatized with A-B-C-D- and their therapeutical use
#817Apolipoprotein AIV as an antidiabetic peptide
#818SUGAR CHAIN ADDED GLP-1 PEPTIDE
#819Double-acylated GLP-1 derivatives with a linker
#820MODIFIED PIG ISLETS FOR DIABETES TREATMENT
#821Exendin-4 peptide analogues
#822Synthesis of glucagon-like peptide
#823GLUCAGON ANALOGUES
#824Solid phase synthesis of h(Gly2)GLP-2
#825PEPTIDE THERAPEUTICS AND METHODS FOR USING SAME
#826METHOD FOR PREPARING EXENATIDE
#827Methods for treating steatotic disease
#828Double-acylated GLP-1 derivatives
#829Glucagon analogues
#830Glucagon-like peptide-1 glycopeptides
#831ANTI-SERUM ALBUMIN BINDING VARIANTS
#832Antidiabetic compounds
#833Glucagon-like peptide-2 analogs
#834Glucagon like peptide analogs, composition, and method of use
#835Glucagon/GLP-1 receptor co-agonists
#836GLP-1 COMPOUNDS
#837GIP analog and hybrid polypeptides with selectable properties
#838GLP-1 receptor agonist compounds having stabilized regions
#839TREATMENT OF CARDIAC CONDITIONS
#840Stabilized insulinotropic peptides and methods of use
#841Glucagon analogues
#842Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
#843Glucagon analogues
#844Methods and compositions for delivering peptides
#845NOVEL GLUCAGON ANALOGUES
#846Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
#847GIP and exendin hybrid polypeptides
#848Dual function fibroblast growth factor 21 proteins
#849Amide based glucagon superfamily peptide prodrugs
#850Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
#851Long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
#852Glucagon analogs exhibiting GIP receptor activity
#853Glucagon superfamily peptides exhbiting G protein coupled receptor activity
#854PEPTIDE DERIVATIVES OF EXENDIN-4
#855Glucagon/GLP-1 receptor co-agonists
#856NOVEL COMPOUNDS AND THEIR EFFECTS ON FEEDING BEHAVIOUR
#857THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES
#858Therapeutic agents comprising insulin and elastin-like peptides
#859Glucagon analogues
#860Methods of treating diabetes using therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptides
#861Methods for identifying a GLP-1 secretagogue
#862Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1]
#863NOVEL GLP-1 DERIVATIVES
#864GLP-1 analogues and derivatives
#865NOVEL GLUCAGON ANALOGUES
#866Glucagon-like peptide-1 analogues and uses thereof
#867Branched Discreet PEG Constructs
#868ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG
#869NOVEL GLUCAGON ANALOGUES
#870Bacterial host cell for the direct expression of peptides
#871PROCESS FOR THE SYNTHESIS OF (AIB8,35)HGLP-1(7-36)-NH2
#872METHODS TO RESTORE GLYCEMIC CONTROL
#873THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES
#874GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS
#875Glucagon/GLP-1 receptor co-agonists
#876Glucagon/GLP-1 receptor co-agonists
#877Methods of enhancing functioning of the large intestine
#878Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
#879Acylated GLP-1 compounds
#880Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
#881GLP-I Agonist And Cardiovascular Complications
#882GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEA
#883Glucagon-like-peptide-2 (GLP-2) analogues
#884GLP-1 compounds
#885Glucagon/GLP-1 receptor co-agonists
#886Acylated exendin-4 compounds
#887Homodimer of insulinotropic peptide analogues and method for preparation thereof and use thereof
#888DRUG FUSIONS AND CONJUGATES WITH EXTENDED HALF LIFE
#889CONJUGATES WITH IMPROVED PHARMACOKINETIC PROPERTIES
#890SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP 1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST
#891Glycosylated Form of Antigenic GLP-1 Analogue
#892TREATMENT OF EYE DISEASES USING ENCAPSULATED CELLS ENCODING AND SECRETING A NEUROPROTECTIVE FACTOR AND/OR AN ANTI-ANGIOGENIC FACTOR
#893RADIOLABELED COMPOUND DIRECTABLE IN VIVO TO TARGET TISSUE AND USE THEREOF
#894Hybrid polypeptides with selectable properties
#895Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
#896Multivalent heteromultimer scaffold design and constructs
#897Protein agent for diabetes treatment and β cell imaging
#898GLP-1 Fusion Peptides
#899Fusion protein of human fibroblast growth factor-21 and exendin-4
#900Glucagon analogs exhibiting GIP receptor activity